Esperion Therapeutics Inc.

NASDAQ:ESPR  
5.80
+0.29 (+5.26%)
Products, Earnings Announcements

Esperion Reports First Quarter 2022 Results

Published: 05/03/2022 12:33 GMT
Esperion Therapeutics Inc. (ESPR) - Esperion Reports First Quarter 2022 Financial Results and Provides Company Update.
Q1 Loss per Share $0.93.
Qtrly Total Revenue Was $18.8 Million Versus $8.0 Million.
Qtrly Research and Development Expense Was $24.3 Million Compared to $28.0 Million for the Comparable Period in 2021.
Research and Development Expenses for the Full Year 2022 Are Expected to Be $100 Million to $110 Million.
Q1 Earnings per Share View $-1.04, Revenue View $15.4 Million -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $18.69 Million
Adjusted EPS is expected to be -$0.93

Next Quarter Revenue Guidance is expected to be $20.84 Million
Next Quarter EPS Guidance is expected to be -$0.91

More details on our Analysts Page.